$BLLN

The Motley Fool on $BLLN (Nov 14, 2026)

AI summary · The Motley Fool

BillionToOne is a buy: its QCT platform's single-molecule counting gives sensitivity traditional diagnostics generally cannot match, and oncology liquid biopsy, which the speaker expects to matter most to growth, grew 96% year over year to about a $68 million annual rate. Revenue beat consensus by about 50%, EPS more than doubled estimates, prenatal revenue rose 41%, and a fifth straight quarter of positive GAAP operating income came with about $9 million free cash flow and $562 million cash; a mid-December minimal residual disease test launch is key to that oncology build-out.

BullishHe framed it in years
“4 Stocks to Buy Before the End of 2026!”
The Motley FoolPublished Nov 14 · 7 passages

Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy

Jump to any passage

7 passages
15:0718:36

For the last stock in today's video, I'll be talking about another name in the healthcare sector, another name that is perhaps a little less well known. I'm trying to change things up a bit.

We sometimes see in the comments that you mention we're only talking about technology stocks, so I'm trying to change the atmosphere a little. We'll see. So, BillionToOne, its symbol is BLLN.

If you are not familiar with it, it is certainly not a name familiar to everyone. They are a molecular diagnostics company. Their platform is built around a type of technology they own that they call Quantitative Counting Templates (QCT).

This platform can essentially detect and measure genetic material with a level of sensitivity that traditional diagnostic companies generally cannot match.

Billion2One applies this technology across two different product lines. The first, which is currently its leading activity, is prenatal testing. They have the first and only non-invasive prenatal test for fetal red blood cell and platelet antigens in the United States.

The second is their activity in the field of oncology, and they are currently building a whole family of liquid biopsy tests that can detect and monitor cancer through a simple blood sample instead of the need for a surgical tissue biopsy.

Oncology is the area that excites me the most, and I believe it will be the most important to the company and its growth story in the future. One of the interesting things is to talk about the platform technology that Billion to One relies on.

Just to explain why it's a bit more distinctive. When blood is drawn from a pregnant woman, a tiny amount of fetal DNA swims freely in her bloodstream, mixed with a much larger amount of her own DNA.

Therefore, extracting a specific and faint embryonic signal from a much larger DNA background is the primary challenge for non-invasive embryonic testing. This same type of basic challenge also appears in cancer tests.

For example, after a tumor is removed, only a handful of cancer DNA fragments may remain, swimming amid millions of healthy fragments. So finding those few fragments is what minimal residual disease tests are really trying to do.

The Billion to One platform works by linking a unique tag to each DNA molecule, enabling it to actually count those molecules rather than estimate their proportion. You can think of it as the difference between weighing a mixed bag of coins to estimate the number of coins in it, versus marking and counting each coin individually.

This precision, that is, precision at the level of a single molecule, is what allows Billion2One to offer these highly accurate diagnostic tests that some established competitors have not yet been able to provide.

This is reflected in the numbers as well. They also announced their quarterly results about a week ago, with total revenue exceeding consensus estimates by about 50% year-over-year.

Diluted earnings per share were more than double what Wall Street had expected. Their revenue from prenatal testing increased by 41% year-on-year. Oncology revenues, which are still a smaller but fastest-growing part of the company, have increased by 96% year-on-year, and now reach an annual rate of about $68 million.

They generated approximately $9 million in free cash flow during the quarter. This was the fifth consecutive quarter in which they achieved positive operating income according to generally accepted accounting principles.

They have approximately $562 million in cash and cash equivalents on their balance sheet.

One of the most important things to watch regarding their oncology work is that they have a new test that will be launched in mid-December. This is a test to detect minimal residual disease.

Essentially, this test is designed to detect microscopic traces of cancer that remain after a patient's tumor has been surgically removed. It is a blood-based test only. It is available for all solid tumors from day one.

It will be released here in the next few weeks. This is essential as they work to expand their range of

Watchpoints

launch of the minimal residual disease blood test slated for mid-December
TickerSays